Geriatrics Unit, Department of Geriatric Care, OrthoGeriatrics and Rehabilitation, E.O. Galliera Hospital, Genova, Italy.
Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy.
Ann Med. 2022 Dec;54(1):2411-2419. doi: 10.1080/07853890.2022.2117407.
Literature suggests that different risks of mortality could influence physicians in prescribing or not anticoagulants in older patients with atrial fibrillation (AF). The Multidimensional Prognostic Index (MPI) can be considered a tool for the detection of multidimensional frailty. The aim of this cross-sectional study was to evaluate whether prescription patterns of oral anticoagulants exist, based on MPI values.
Older hospitalised patients (age ≥ 65 years) with non-valvular AF were included across 24 European centres. MPI was calculated using validated and standardised tools derived from a comprehensive geriatric assessment. Other functional and clinical information were collected to calculate indexes specific for haemorrhagic and thromboembolic risk in AF.
Altogether, 2,012 participants affected by AF (mean age was 83.2 ± 7.5, range: 65-104 years), with a higher presence of women (57.0%), were included. Overall, 440 took vitamin K antagonists VKAs (22.0%), 667 (33.4%) direct oral anticoagulants (DOACs), whilst 44.6% did not take any anticoagulant treatment. Prescription of anticoagulants was associated with MPI values, with people taking anticoagulants having lower mean MPI values. Anticoagulant therapy was not used in 53.1% of the group with the highest risk of mortality, compared with 32.3% of those in the group with the lowest mortality risk. People with higher scores in MPI were less frequently treated with anticoagulant therapy, after adjusting for several potential confounders.
The EURopean study of Older Subjects with Atrial Fibrillation (EUROSAF) suggested that almost half of the older persons with AF do not receive anticoagulants and that MPI is an important determinant in prescribing or not anticoagulants. : https://clinicaltrials.gov/ct2/show/NCT02973984KEY POINTSAtrial fibrillation is a common condition in older people. The data regarding the use of anticoagulants is mainly derived from randomised controlled trials that do not include a sufficient number of older frail people.Our study suggests that a consistent part of older people affected by atrial fibrillation was not treated with anticoagulants, in particular, older frail patients; however, it is unclear if this choice is supported or not by evidence.The prognostic evaluation through the multidimensional prognostic index could be useful information for the choice in the prescription of anticoagulants in older people affected by atrial fibrillation.
文献表明,不同的死亡率风险可能会影响医生对老年心房颤动(AF)患者是否开具抗凝药物。多维预后指数(MPI)可被视为检测多维虚弱的一种工具。本横断面研究的目的是评估是否存在基于 MPI 值的口服抗凝药物处方模式。
在 24 个欧洲中心纳入了年龄≥65 岁的非瓣膜性 AF 住院患者。使用源自全面老年评估的验证和标准化工具计算 MPI。收集其他功能和临床信息,以计算 AF 出血和血栓栓塞风险的特定指数。
共纳入 2012 名患有 AF 的参与者(平均年龄为 83.2±7.5 岁,范围为 65-104 岁),其中女性(57.0%)居多。总体而言,440 人服用维生素 K 拮抗剂 VKAs(22.0%),667 人(33.4%)服用直接口服抗凝剂 DOACs,而 44.6%的人未接受任何抗凝治疗。抗凝药物的处方与 MPI 值相关,服用抗凝药物的人的平均 MPI 值较低。在死亡率风险最高的组中,53.1%的人未使用抗凝治疗,而在死亡率风险最低的组中,这一比例为 32.3%。调整了几个潜在混杂因素后,MPI 得分较高的人较少接受抗凝治疗。
EURopean study of Older Subjects with Atrial Fibrillation(EUROSAF)研究表明,近一半的老年 AF 患者未接受抗凝治疗,MPI 是决定是否开具抗凝药物的重要因素。